PHARMExcel shortlisted in the investors in people awards 2022
PHARMExcel has made the final shortlist for The Award for Small Employer of the Year in The Investors in People Awards 2022.
PHARMExcel CEO nominated for Best Businesswoman of the Year Award
PHARMExcel is delighted to celebrate the achievements of its Founder and CEO, Yvanne Enever, who has been nominated Businesswoman of the Year at the SME Hertfordshire Business Awards 2022.
PHARMExcel shortlisted to win Business of the Year Award
PHARMExcel is proud to be shortlisted to win Business of the Year 2022 at the SME Hertfordshire Business Awards. The award recognises innovation, commercial boldness and outstanding management practices.
Great Teams Don’t Just Happen
How to support employee mental health and create a happy and productive team. PHARMExcel explores new well-being initiatives for office and remote workers.
PHARMExcel are pleased to announce their latest Lancet publication on Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters
How working with an agile CRO gets you more from your clinical trial budget
The process of taking a pharmaceutical drug through its drug discovery pathway can be challenging, time consuming, and expensive. It’s why more and more leading biotech and pharma companies choose to outsource clinical research work to contract research organisations (CROs) instead.
PHARMExcel are pleased to announce the publication of the persistence of immunogenicity after seven Covid -19 vaccines given as third boosters
PHARMExcel celebrates 13 successful years!
This month PHARMExcel reaches yet another milestone as it celebrates 13 years of successful business.
PHARMExcel are delighted to announce their future collaboration with DIOSynVax to support the delivery of their forthcoming clinical trial program.
This programme, (supported by CEPI funding), will provide the infrastructure to help design and select the lead antigen through proof-of-concept preclinical studies, progressing to initial clinical development through Phase I/II studies. DIOSynVax aim to establish clinical proof of concept for a novel vaccine candidate with the potential to provide broad protection against Sarbecovirus, Merbecovirus, Embecovirus and Nobecovirus.